Vynleads Bets on ‘Done With’ Blueprint to Tackle Chronic Disease

ROCK HILL, SC – January 28, 2026 – Wellness technology company Vynleads (OTCQB: VYND) has unveiled an ambitious new digital platform aimed at fundamentally changing how people manage chronic, lifestyle-driven health conditions. The “Done With” Lifestyle Blueprint™ (DWX) platform is designed to provide clear, actionable daily routines, moving beyond simple data tracking to offer a structured path toward sustainable health.

The company’s first product, an eight-week program and app called “Done With Diabetes™,” is slated to launch next month. It targets the more than 40 million Americans living with type 2 diabetes and prediabetes, promising to replace the often-confusing and overwhelming nature of disease management with a clear, step-by-step guide.

“Our mission is to help people reach a place where they truly feel done. Done starting over, done feeling overwhelmed, and done going at it alone,” said Alex Mannine, Co-founder & CEO of Vynleads, in the company’s announcement. The new platform, he explained, is how Vynleads plans to scale this mission into a suite of condition-specific programs grounded in science and designed for real-world application.

A Crowded Market for Digital Health

Vynleads is entering a fiercely competitive and rapidly expanding arena. The global market for digital diabetes management is projected to soar from $11.2 billion in 2022 to $32.2 billion by 2027, attracting a host of well-established players. Giants like Livongo (now part of Teladoc Health), Omada Health, and Noom have already captured significant market share with their own platforms that combine connected devices, personalized coaching, and educational content.

These competitors have set a high bar, offering comprehensive services that are often integrated with corporate wellness programs and health insurance plans. Vynleads aims to differentiate itself not by tracking more data, but by providing more structure. While many apps focus on collecting metrics like blood sugar readings and calorie counts, the “Done With” platform’s core promise is its “Lifestyle Blueprint,” which translates complex medical and lifestyle science into simple, repeatable daily actions.

This focus on guided action rather than passive data collection could be a key differentiator. The platform is built for consumers who feel inundated with information but lack a clear plan for what to do next. By structuring daily routines around nutrition, movement, sleep, and stress management, Vynleads is betting that clarity is the missing ingredient for long-term adherence and success.

The 'Lifestyle Blueprint' Methodology

The “Done With Diabetes™” program is a 56-day digital experience designed to build progressive habits. Rather than simply telling users to eat better or exercise more, it provides concrete, daily guidance. This includes real-world portion guidance, meal-building strategies, and approachable movement routines designed to fit into busy schedules.

The program’s methodology is rooted in the principles of lifestyle medicine, an evidence-based approach strongly endorsed by organizations like the American Diabetes Association and the American Heart Association for managing chronic conditions. The app will feature education on low-calorie dietary approaches, including concepts from Very Low-Calorie Diets (VLCD) for learning purposes, and practices to improve sleep and manage stress—two factors critically linked to metabolic health.

To personalize this experience, Vynleads has incorporated an AI-powered coach, dubbed “Dr. Smith AI Coach,” into its protocol. This digital coach is intended to provide interactive support and guidance, helping users navigate the program and connect their daily choices to visible progress through simple tracking metrics. The goal is to create a feedback loop that reinforces positive behaviors and builds a user’s confidence in their ability to manage their health.

High Stakes for a Pre-Revenue Venture

While the market opportunity is vast, the challenge for Vynleads is immense. The company is currently pre-revenue, reporting accumulated losses of $2.8 million as of last November and no revenue for the fiscal years 2023 and 2024. With negative equity and a stock price hovering in the lower end of its recent range, the success of the “Done With” platform is not just a strategic priority—it is an existential test.

The upcoming app launch represents the company’s first major step in converting its vision into a viable business. Success will depend entirely on its ability to acquire users in a market dominated by bigger, better-funded competitors and to prove that its structured approach can deliver tangible health outcomes and retain subscribers over the long term. The emotionally resonant “Done With” branding may attract users frustrated with their current options, but the platform’s performance and user experience will ultimately determine if they stay.

Navigating Regulation and Future Growth

Beyond market competition, Vynleads must navigate the complex regulatory landscape of digital health. By positioning its app as a tool that “translates wellness principles” and supports “lifestyle change,” the company appears to be targeting the “general wellness” category, which typically avoids the stringent oversight the U.S. Food and Drug Administration (FDA) applies to products classified as medical devices. This strategy allows for a faster path to market but requires careful marketing to avoid making explicit claims about treating or curing disease.

Vynleads has already laid out an ambitious roadmap for expansion. Following the diabetes program, the company plans to extend its DWX ecosystem to other high-impact conditions, with “Done With Heart Disease” and “Done With Depression” already in the pipeline. This long-term vision underscores the scalability of the “Lifestyle Blueprint” concept, which could be adapted to a wide range of chronic conditions where daily habits are paramount.

The coming weeks will be critical. As the “Done With Diabetes™” app prepares to hit digital storefronts next month, its reception by consumers and the medical community will offer the first real verdict on whether Vynleads’ blueprint for clarity can build a sustainable business and make a meaningful impact on the lives of those managing chronic illness.